You are here

Study: Pitavastatin (Livalo) More Effective Than Pravastatin at Lowering LDL-C in HIV Patients

Dyslipidemia common with HIV infection (Mar. 7)

Results have been announced from a study that evaluated the efficacy of pitavastatin (Livalo, Kowa Pharmaceuticals/Eli Lilly) compared with pravastatin in reducing low-density lipoprotein cholesterol (LDL-C) in human immunodeficiency virus (HIV)-infected adults with dyslipidemia. The study was designed as a superiority trial for the primary endpoint — percent reduction in LDL-C — and evaluated HIV-infected adults with dyslipidemia, with and without viral hepatitis B or C infection. The study met its primary endpoint.

A total of 252 patients were randomly assigned to receive once-daily doses of pitavastatin 4 mg or pravastatin 40 mg for 12 weeks. Pitavastatin achieved a significantly greater reduction in LDL-C compared with pravastatin (–49.4 mg/dL [31% reduction] vs. –33.6 mg/dL [21% reduction], respectively; P th Conference on Retroviruses and Opportunistic Infections (CROI), held in Atlanta, Georgia.

Dyslipidemia is common in people with HIV infection. HIV-infected adults have an increased risk for cardiovascular disease due to many factors, including lipid abnormalities.

The overall incidence of treatment-emergent adverse events (AEs) was 61.1% for pitavastatin and 62.7% for pravastatin. The most frequently reported treatment-emergent AEs in either treatment group included diarrhea (5.2%), upper respiratory tract infection (5.2%), sinusitis (4.8%), headache (4.0%), nausea (4.0%), nasopharyngitis (3.6%), and blood creatine phosphokinase increased (3.2%).

Pitavastatin (Livalo) is an HMG-CoA reductase inhibitor indicated as an adjunctive therapy to diet to reduce elevated total cholesterol, LDL-C, apolipoprotein B, and triglycerides, and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hyperlipidemia or mixed dyslipidemia. The drug was launched in the U.S. in June 2010.

Source: Eli Lilly; March 7, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs